论文部分内容阅读
目的:观察国产吉西他滨(泽菲)联合氟尿嘧啶治疗晚期胰腺癌的临床疗效及安全性。方法:32例中晚期胰腺癌患者,予以国产吉西他滨(1 000mg/m2)联合氟尿嘧啶治疗,21天为1个疗程,接受2个疗程的化疗后,按照WHO标准进行评价。结果:32例均可评价疗效,中位生存7.3个月,临床有效率40.6%(13/32),临床受益率(CBR)65.6%(21/32),胃肠道反应37.5%(12/32),骨髓抑制40.6%(13/32),无治疗相关性死亡病例。结论:西他滨联合氟尿嘧啶治疗晚期胰腺癌疗效较好,可明显提高患者的生存质量,不良反应可耐受。
Objective: To observe the clinical efficacy and safety of domestic gemcitabine (Zephyphy) in combination with fluorouracil in the treatment of advanced pancreatic cancer. Methods: Thirty-two patients with advanced pancreatic cancer were treated with domestic gemcitabine (1 000 mg / m2) plus fluorouracil for 21 days. After two courses of chemotherapy, they were evaluated according to WHO criteria. Results: The curative effect was evaluated in 32 cases. The median survival time was 7.3 months, the clinical effective rate was 40.6% (13/32), the clinical benefit rate (CBR) was 65.6% (21/32), the gastrointestinal reaction rate was 37.5% 32), bone marrow suppression 40.6% (13/32), no treatment-related deaths. Conclusion: The combination of citalopham and fluorouracil is effective in the treatment of advanced pancreatic cancer, which can significantly improve the quality of life of patients and can tolerate adverse reactions.